We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biophytis (BPTS) Soars 73% on Partnership With Skyepharma
Read MoreHide Full Article
Biophytis S.A. enters into an agreement with Skyepharma, a French company, for the production of batches of its lead candidate, Sarconeos (BIO101), developed to treat severe forms of COVID-19. Following this development, shares of the company soared almost 73% on Sep 25.
Under the terms of agreement, Skyepharma will develop finished product batches of Sarconeos, adhering to Good Manufacturing Practice (GMP) standards, necessary for regulatory approvals. The finished products are based on an active ingredient for Sarconeos, which is also produced by a French company, SEQENS.
The partnership is also intended to facilitate the submission of marketing authorization applications for Sarconeos.
With Skyepharma's extensive experience in pharmaceutical production and compliance with GMP standards, the partnership secures the production of finished product batches of Sarconeos.
Shares of Biophytis have lost 59.7% year to date compared with the industry’s 16.0% decline.
Image Source: Zacks Investment Research
Sarconeos is an orally administered small molecule being developed for the treatment of age- related neuromuscular and cardiorespiratory (COVID-19) diseases. The candidate is also evaluated in two other indications — sarcopenia and duchenne muscular dystrophy.
Like Influenza, COVID-19 has become an endemic respiratory infectious disease that can lead to acute respiratory distress syndrome in elderly, immunocompromised or co-morbid patients.
In clinical studies, patients who received Sarconeos experienced a significant 44% reduction in the risk of respiratory failure or early death compared to placebo. These results suggest that Sarconeos has the potential to become the new therapeutic option alongside antiviral or anti-inflammatory to treat patients with severe forms of COVID-19.
In the past 90 days, the Zacks Consensus Estimate forAnika Therapeutics has narrowed from a loss of $1.41 per share to a loss of $1.24 for 2023. The bottom-line estimate has widened from a loss of 79 cents to a loss of 82 cents for 2024 during the same time frame. Shares of the company have lost 37.5% year to date.
ANIK’s earnings beat estimates in one of the trailing four quarters and missed the mark in the remaining three, delivering an average negative surprise of 32.12%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to a loss of $2.77 for 2024 during the same time frame. Shares of the company have lost 28.8% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 59.1% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Biophytis (BPTS) Soars 73% on Partnership With Skyepharma
Biophytis S.A. enters into an agreement with Skyepharma, a French company, for the production of batches of its lead candidate, Sarconeos (BIO101), developed to treat severe forms of COVID-19. Following this development, shares of the company soared almost 73% on Sep 25.
Under the terms of agreement, Skyepharma will develop finished product batches of Sarconeos, adhering to Good Manufacturing Practice (GMP) standards, necessary for regulatory approvals. The finished products are based on an active ingredient for Sarconeos, which is also produced by a French company, SEQENS.
The partnership is also intended to facilitate the submission of marketing authorization applications for Sarconeos.
With Skyepharma's extensive experience in pharmaceutical production and compliance with GMP standards, the partnership secures the production of finished product batches of Sarconeos.
Shares of Biophytis have lost 59.7% year to date compared with the industry’s 16.0% decline.
Image Source: Zacks Investment Research
Sarconeos is an orally administered small molecule being developed for the treatment of age- related neuromuscular and cardiorespiratory (COVID-19) diseases. The candidate is also evaluated in two other indications — sarcopenia and duchenne muscular dystrophy.
Like Influenza, COVID-19 has become an endemic respiratory infectious disease that can lead to acute respiratory distress syndrome in elderly, immunocompromised or co-morbid patients.
In clinical studies, patients who received Sarconeos experienced a significant 44% reduction in the risk of respiratory failure or early death compared to placebo. These results suggest that Sarconeos has the potential to become the new therapeutic option alongside antiviral or anti-inflammatory to treat patients with severe forms of COVID-19.
Zacks Rank & Stocks to Consider
Biophytis SA Sponsored ADR Price and Consensus
Biophytis SA Sponsored ADR price-consensus-chart | Biophytis SA Sponsored ADR Quote
Biophytiscurrently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same industry are Anika Therapeutics (ANIK - Free Report) , Annovis Bio (ANVS - Free Report) and Corcept Therapeutics (CORT - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 90 days, the Zacks Consensus Estimate forAnika Therapeutics has narrowed from a loss of $1.41 per share to a loss of $1.24 for 2023. The bottom-line estimate has widened from a loss of 79 cents to a loss of 82 cents for 2024 during the same time frame. Shares of the company have lost 37.5% year to date.
ANIK’s earnings beat estimates in one of the trailing four quarters and missed the mark in the remaining three, delivering an average negative surprise of 32.12%.
In the past 90 days, the Zacks Consensus Estimate for Annovis Bio has narrowed from a loss of $4.89 per share to a loss of $4.38 for 2023. The bottom-line estimate has narrowed from a loss of $3.18 to a loss of $2.77 for 2024 during the same time frame. Shares of the company have lost 28.8% year to date.
ANVS’ earnings beat estimates in three of the trailing four quarters and missed the mark in one, delivering an average surprise of 13.40%.
In the past 90 days, the Zacks Consensus Estimate for Corcept’s earnings has gone up from 62 cents per share to 78 cents for 2023. The bottom-line estimate has also improved from 61 cents to 83 cents for 2024 during the same time frame. Shares of the company have rallied 59.1% year to date.
CORT’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 6.99%.